NicOx invests £2million in UK ophthalmic company

Article

French pharmaceutical company NicOx has announced its decision to invest £2million into UK firm Altacor in order to create an international ophthalmic firm.

French pharmaceutical company NicOx has announced its decision to invest £2million into UK firm Altacor in order to create an international ophthalmic firm.

Altacor, specializing in treatments for ocular surface disease, ocular infection and glaucoma, hopes to build a late-stage development and commercial ophthalmology company with NicOx. They aim to focus on therapeutics, diagnostics and devices.

he collaboration will provide the opportunity to develop Altacor's leading candidate ALT-005, a surgical antiseptic for ocular infection, and SOLO, a device used to aid IOL insertion.

Dr Fran Crawfrod, Chief Executive Officer (CEO) of Altacor, commented, "Altacor and NicOx have developed a strong working relationship. The companies are strategically well aligned, both having similar perspectives on the emerging ophthalmology market. We therefore believe NicOx is an excellent partner for Altacor and the investment announced today will enable us to secure the development of the portfolio. NicOx’s R&D and partnering expertise will be of significant benefit as we progress our late-stage pipeline.”

Michele Garufi, CEO of NicOx, said, "The execution of this transaction is the first step in executing our strategy to become an international ophthalmology company. The acquisition of Altacor will also provide NicOx with an established infrastructure supporting sales in the UK and Ireland as a base for the future launch of additional products."

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.